Literature DB >> 18669611

Kupffer cell products and interleukin 1beta directly promote VLDL secretion and apoB mRNA up-regulation in rodent hepatocytes.

Nerea Bartolomé1, Beatriz Arteta, María José Martínez, Yolanda Chico, Begoña Ochoa.   

Abstract

Plasma VLDL accumulation in Gram-negative sepsis is partly ascribed to an increased hepatic VLDL production driven by pro-inflammatory cytokines. We previously showed that hepatocytes of the Kupffer cell (KC)-rich periportal area are major contributors to enhanced VLDL production in lipopolysaccharide (LPS)-injected rats. However, it remains to be established whether KC generated products directly affect the number (apoB) and composition of secreted VLDL. Using rat primary cells, we show here that hepatocytes respond to stimulation by soluble mediators released by LPS-stimulated Kupffer cells with enhanced secretion of apoB and triglycerides in phospholipid-rich VLDL particles. Unstimulated KC products also augmented the secretion of normal VLDL, doubling apoB mRNA abundance. IL-1beta treatment resulted in concentration-dependent increases of hepatocyte apoB mRNA and protein secretion, increases that were greater, but not additive, when combined with IL-6 and TNF-alpha. Lipid secretion and MTP mRNA levels were unaffected by cytokines. In summary: (i) enhanced secretion of phospholipid-rich VLDL particles is a net hepatocyte response to LPS-stimulated KC products, which gives a clue about the local role of Kupffer cells in septic dyslipidemia induction; and (ii) pro-inflammatory cytokines act redundantly to enhance apoB secretion involving translational apoB up-regulation, but other humoral components or KC mediators are necessary to accomplish increased lipid association.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18669611     DOI: 10.1177/1753425908094718

Source DB:  PubMed          Journal:  Innate Immun        ISSN: 1753-4259            Impact factor:   2.680


  13 in total

1.  Caspase-1 deficiency in mice reduces intestinal triglyceride absorption and hepatic triglyceride secretion.

Authors:  Janna A van Diepen; Rinke Stienstra; Irene O C M Vroegrijk; Sjoerd A A van den Berg; Daniela Salvatori; Guido J Hooiveld; Sander Kersten; Cees J Tack; Mihai G Netea; Johannes W A Smit; Leo A B Joosten; Louis M Havekes; Ko Willems van Dijk; Patrick C N Rensen
Journal:  J Lipid Res       Date:  2012-11-17       Impact factor: 5.922

2.  Interleukin-6 mediates hepatic hypersecretion of apolipoprotein B.

Authors:  Janet D Sparks; Joanne Cianci; Jenny Jokinen; Li Sheng Chen; Charles E Sparks
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-07-22       Impact factor: 4.052

3.  Interleukin 1β regulation of FoxO1 protein content and localization: evidence for a novel ceramide-dependent mechanism.

Authors:  Aneta Dobierzewska; Lihua Shi; Alexander A Karakashian; Mariana N Nikolova-Karakashian
Journal:  J Biol Chem       Date:  2012-10-26       Impact factor: 5.157

4.  Naringenin prevents cholesterol-induced systemic inflammation, metabolic dysregulation, and atherosclerosis in Ldlr⁻/⁻ mice.

Authors:  Julia M Assini; Erin E Mulvihill; Brian G Sutherland; Dawn E Telford; Cynthia G Sawyez; Sarah L Felder; Sanjiv Chhoker; Jane Y Edwards; Robert Gros; Murray W Huff
Journal:  J Lipid Res       Date:  2012-12-26       Impact factor: 5.922

Review 5.  From whole body to cellular models of hepatic triglyceride metabolism: man has got to know his limitations.

Authors:  Charlotte J Green; Camilla Pramfalk; Karl J Morten; Leanne Hodson
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-10-28       Impact factor: 4.310

6.  Therapeutic potential of stem cells from human exfoliated deciduous teeth infusion into patients with type 2 diabetes depends on basal lipid levels and islet function.

Authors:  Wenwen Li; Xuan Jiao; Jingyun Song; Bingdong Sui; Zhili Guo; Yingji Zhao; Jun Li; Songtao Shi; Qin Huang
Journal:  Stem Cells Transl Med       Date:  2021-03-04       Impact factor: 6.940

7.  Very-low-density lipoprotein: complex particles in cardiac energy metabolism.

Authors:  You-Guo Niu; Rhys D Evans
Journal:  J Lipids       Date:  2011-07-03

Review 8.  Function and Therapeutic Potential of Mesenchymal Stem Cells in Atherosclerosis.

Authors:  Feifei Li; Xia Guo; Shi-You Chen
Journal:  Front Cardiovasc Med       Date:  2017-05-22

9.  Mesenchymal Stem Cells Reduce Murine Atherosclerosis Development.

Authors:  Vanessa Frodermann; Janine van Duijn; Melissa van Pel; Peter J van Santbrink; Ilze Bot; Johan Kuiper; Saskia C A de Jager
Journal:  Sci Rep       Date:  2015-10-22       Impact factor: 4.379

10.  Profiling of promoter occupancy by the SND1 transcriptional coactivator identifies downstream glycerolipid metabolic genes involved in TNFα response in human hepatoma cells.

Authors:  Enara Arretxe; Sandra Armengol; Sarai Mula; Yolanda Chico; Begoña Ochoa; María José Martínez
Journal:  Nucleic Acids Res       Date:  2015-08-31       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.